BG Medicine, Inc. / Fundamentals
Income statement
- Net revenue
€1.34M - Cost of goods sold
€431.59K - Gross profit
€904.13K - SG&A expenses
€3.34M - R&D expenses
€1.51M - EBITDA
-€4.31M - D&A
€74.21K - EBIT
-€3.95M - Interest expenses
€135.62K - EBT
-€4.52M - Tax expenses
-€37.53K - Net income
-€4.52M
Cash flow statement
- Net deferred tax
€183.38K - Non-cash items
€632.89K - Changes in working capital
-€20.47K - Operating cash flow
-€3.13M - Capex
€0.00 - Other investing cash flow
€11.09 - Net investing cash flow
€11.09K - Total cash dividends paid
€0.00 - Issuance of common stock
€2.13M - Debt repayment
-€2.55M - Other financing cash flow
€1.31M - Net financing cash flow
€900.72K - Foreign exchange effects
€0.00 - Net change in cash
-€2.22M - Cash at end of period
€1.30M - Free cash flow
-€3.13M
Balance sheet
- Cash and cash equivalents
€1.30M - Cash and short-term investments
€1.30M - Total receivables
€154.38K - Inventory
€123.68K - Other current assets
€85.30K - Total current assets
€1.66M - Property, plant & equipment
€9.38K - Goodwill
€0.00 - Intangible assets
€65.68K - Long-term investments
€0.00 - Other non-current assets
€80.18K - Total non-current assets
€155.24K - Total assets
€1.82M - Accounts payable
€475.95K - Short-term debt
€0.00 - Other current liabilities
€530.54K - Total current liabilities
€1.01M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€2.30M - Total non-current liabilities
€2.50M - Total liabilities
€3.50M - Common stock
€9.38K - Retained earnings
-€141.85M - Other equity
-€2.21M - Total equity
-€1.69M - Total liabilities and shareholders' equity
€1.82M
Company information
- Market capitalization
€9.38 - Employees
5 - Enterprise Value
€1.10K
Company ratios
- Gross margin
-
67.7% Much better than peer group: -1,345.6% - EBITDA margin
-
-322.9% Much worse than peer group: 488,969,060,672,693,300.0% - EBIT margin
-
-295.6% Much worse than peer group: 7,313,423,256,348,147,000.0% - EBT margin
-
-338.6% Much better than peer group: -319,223,324,584,255,900.0% - Net margin
-
-338.6% Much better than peer group: -319,223,324,584,256,350.0% - ROE
-
268.3% Much better than peer group: -40.6% - ROA
-
-248.6% Much worse than peer group: -67.3% - Asset turnover
-
73.4% Much better than peer group: 5.1% - FCF margin
-
-234.2% Much worse than peer group: 19,347,383,382,145,780,000.0% - FCF yield
-33,336,363.6% - Efficiency ratio
422.9% - Net sales per employee
-
€267.14K - Net income per employee
-
-€904.47K